<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">33527177</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>20</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1179-1942</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>44</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>May</Month>
            </PubDate>
          </JournalIssue>
          <Title>Drug safety</Title>
          <ISOAbbreviation>Drug Saf</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Upadacitinib in Rheumatoid Arthritis: A Benefit-Risk Assessment Across a Phase III Program.</ArticleTitle>
        <Pagination>
          <StartPage>515</StartPage>
          <EndPage>530</EndPage>
          <MedlinePgn>515-530</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s40264-020-01036-w</ELocationID>
        <Abstract>
          <AbstractText>Treating to a target of clinical remission or low disease activity is an important principle for managing rheumatoid arthritis (RA). Despite the availability of biologic disease-modifying antirheumatic drugs (bDMARDs), a substantial proportion of patients with RA do not achieve these treatment targets. Upadacitinib is a once-daily, oral Janus kinase (JAK) inhibitor with increased selectivity for JAK1 over JAK2, JAK3, and tyrosine kinase 2. The SELECT phase III upadacitinib clinical program comprised five pivotal trials of approximately 4400 patients with RA, including inadequate responders (IR) to conventional synthetic (cs)DMARDs or bDMARDs. This review aims to provide insights into the benefit-risk profile of upadacitinib in patients with RA. Upadacitinib 15 mg once daily, in combination with csDMARDs or as monotherapy, achieved all primary and ranked secondary endpoints in the five pivotal trials across csDMARD-naïve, csDMARD-IR, and bDMARD-IR populations. Upadacitinib 15 mg also demonstrated significantly higher rates of remission and low disease activity in all five pivotal trials, compared with placebo, methotrexate, or adalimumab. Labeled warnings of JAK inhibitors include serious infections, herpes zoster, malignancies, major cardiovascular events, and venous thromboembolic events. Short- and long-term integrated analyses showed that upadacitinib 15 mg was associated with increased risk of herpes zoster and creatine phosphokinase elevations compared with methotrexate and adalimumab but otherwise had comparable safety with these active comparators. This review suggests that upadacitinib 15 mg had a favorable benefit-risk profile. The safety of upadacitinib will continue to be monitored in long-term extensions and post-marketing studies.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Conaghan</LastName>
            <ForeName>Philip G</ForeName>
            <Initials>PG</Initials>
            <Identifier Source="ORCID">0000-0002-3478-5665</Identifier>
            <AffiliationInfo>
              <Affiliation>Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and National Institute for Health Research Leeds Biomedical Research Centre, Leeds, UK. p.conaghan@leeds.ac.uk.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mysler</LastName>
            <ForeName>Eduardo</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Organización Médica de Investigación, Buenos Aires, Argentina.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tanaka</LastName>
            <ForeName>Yoshiya</ForeName>
            <Initials>Y</Initials>
            <Identifier Source="ORCID">0000-0002-0807-7139</Identifier>
            <AffiliationInfo>
              <Affiliation>The First Department of Internal Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Da Silva-Tillmann</LastName>
            <ForeName>Barbara</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>AbbVie Inc., North Chicago, IL, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shaw</LastName>
            <ForeName>Tim</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>AbbVie Ltd, Maidenhead, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>John</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>AbbVie Inc., North Chicago, IL, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ferguson</LastName>
            <ForeName>Ryan</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>AbbVie Inc., North Chicago, IL, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Enejosa</LastName>
            <ForeName>Jeffrey V</ForeName>
            <Initials>JV</Initials>
            <AffiliationInfo>
              <Affiliation>AbbVie Inc., North Chicago, IL, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cohen</LastName>
            <ForeName>Stanley</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0002-9226-979X</Identifier>
            <AffiliationInfo>
              <Affiliation>Metroplex Clinical Research Center, Dallas, TX, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nash</LastName>
            <ForeName>Peter</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Griffith University, Brisbane, QLD, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rigby</LastName>
            <ForeName>William</ForeName>
            <Initials>W</Initials>
            <Identifier Source="ORCID">0000-0002-1382-7299</Identifier>
            <AffiliationInfo>
              <Affiliation>Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Burmester</LastName>
            <ForeName>Gerd</ForeName>
            <Initials>G</Initials>
            <Identifier Source="ORCID">0000-0001-7518-1131</Identifier>
            <AffiliationInfo>
              <Affiliation>Charité-Universitätsmedizin Berlin, Berlin, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <Acronym>DH_</Acronym>
            <Agency>Department of Health</Agency>
            <Country>United Kingdom</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>02</Month>
          <Day>02</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Drug Saf</MedlineTA>
        <NlmUniqueID>9002928</NlmUniqueID>
        <ISSNLinking>0114-5916</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018501">Antirheumatic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006575">Heterocyclic Compounds, 3-Ring</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000075242">Janus Kinase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>4RA0KN46E0</RegistryNumber>
          <NameOfSubstance UI="C000613732">upadacitinib</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>FYS6T7F842</RegistryNumber>
          <NameOfSubstance UI="D000068879">Adalimumab</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>YL5FZ2Y5U1</RegistryNumber>
          <NameOfSubstance UI="D008727">Methotrexate</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000068879" MajorTopicYN="N">Adalimumab</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018501" MajorTopicYN="Y">Antirheumatic Agents</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001172" MajorTopicYN="Y">Arthritis, Rheumatoid</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006562" MajorTopicYN="Y">Herpes Zoster</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006575" MajorTopicYN="N">Heterocyclic Compounds, 3-Ring</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000075242" MajorTopicYN="Y">Janus Kinase Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008727" MajorTopicYN="N">Methotrexate</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>Philip G. Conaghan has received consultancy or speakers’ bureau fees from AbbVie, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Flexion Therapeutics, Galapagos, Gilead, Janssen, Novartis, and Pfizer. Eduardo Mysler has received research grants and/or consulting fees from AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen, Pfizer, Roche, and Sandoz. Yoshiya Tanaka has received speaking fees and/or honoraria from AbbVie GK, Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, Eli Lilly Japan KK, Janssen Pharmaceutical KK, Mitsubishi-Tanabe Pharma, Novartis, Pfizer Japan Inc., Takeda, Teijin, and YL Biologics and research grants from Asahi-Kasei Pharma, Bristol-Myers Squibb, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, Mitsubishi-Tanabe Pharma, Ono Pharmaceutical, Sanofi KK, Takeda, and UCB Japan. Barbara Da Silva-Tillmann, Tim Shaw, John Liu, Ryan Ferguson, and Jeffrey V. Enejosa are employees of AbbVie and may own AbbVie stock or options. Stanley Cohen has received grant money/research support from, and has acted as consultant to, Amgen, AbbVie, Boehringer Ingelheim, Pfizer, and Sandoz. Peter Nash has received funding for clinical trials, research grants, and honoraria for lectures and advice from AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Gilead, Janssen, Novartis, Pfizer, Roche, Sandoz, Sanofi-Aventis, and UCB. William Rigby has received grant/research support from, and has acted as a consultant for, AbbVie, Bristol-Myers Squibb, Eli Lilly, Pfizer, Roche, and Sun Pharma. Gerd Burmester has acted as consultant and participated in speakers’ bureaus for AbbVie, Eli Lilly, Gilead, and Pfizer.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>12</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33527177</ArticleId>
        <ArticleId IdType="pmc">PMC8053169</ArticleId>
        <ArticleId IdType="doi">10.1007/s40264-020-01036-w</ArticleId>
        <ArticleId IdType="pii">10.1007/s40264-020-01036-w</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Smolen JS, Aletaha D, Barton A, et al.  Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4:18001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29417936</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet. 2017;389:2328–2337.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28612747</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. Semin Arthritis Rheum. 2006;36:182–188.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17045630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamanaka H, Sugiyama N, Inoue E, et al.  Estimates of the prevalence of and current treatment practices for rheumatoid arthritis in Japan using reimbursement data from health insurance societies and the IORRA cohort (I) Mod Rheumatol. 2013;24:33–40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24261756</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sengul I, Akcay-Yalbuzdag S, Ince B, et al.  Comparison of the DAS28-CRP and DAS28-ESR in patients with rheumatoid arthritis. Int J Rheum Dis. 2015;18:640–645.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26013310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smolen JS, Landewé R, Bijlsma J, et al.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79:685–699.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31969328</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh JA, Saag KG, Bridges SL, Jr, et al.  2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2016;68:1–25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26545825</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang W, Zhou H, Liu L. Side effects of methotrexate therapy for rheumatoid arthritis: a systematic review. Eur J Med Chem. 2018;158:502–516.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30243154</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bello AE, Perkins EL, Jay R, et al.  Recommendations for optimizing methotrexate treatment for patients with rheumatoid arthritis. Open Access Rheumatol. 2017;9:67–79.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5386601</ArticleId>
            <ArticleId IdType="pubmed">28435338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smolen JS, Breedveld FC, Burmester GR, et al.  Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75:3–15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4717393</ArticleId>
            <ArticleId IdType="pubmed">25969430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu C, Jin S, Wang Y, et al.  Remission rate and predictors of remission in patients with rheumatoid arthritis under treat-to-target strategy in real-world studies: a systematic review and meta-analysis. Clin Rheumatol. 2019;38:727–738.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30341703</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Combe B, Lula S, Boone C, et al.  Effects of biologic disease-modifying anti-rheumatic drugs on the radiographic progression of rheumatoid arthritis: a systematic literature review. Clin Exp Rheumatol. 2018;36:658–667.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29600931</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nam JL, Ramiro S, Gaujoux-Viala C, et al.  Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2014;73:516–528.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24399231</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kalden JR, Schulze-Koops H. Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment. Nat Rev Rheumatol. 2017;13:707–718.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29158574</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rubbert-Roth A, Finckh A. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res Ther. 2009;11:S1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2669237</ArticleId>
            <ArticleId IdType="pubmed">19368701</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>EMA. Xeljanz (tofacitinib): Summary of product characteristics 2017. https://www.ema.europa.eu/en/documents/product-information/xeljanz-epar-product-information_en.pdf. Accessed 1 Dec 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>EMA. Olumiant (baricitinib): Summary of product characteristics 2017. https://www.ema.europa.eu/en/documents/product-information/olumiant-epar-product-information_en.pdf. Accessed 1 Dec 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>EMA. RINVOQ (upadacitinib). Summary of product characteristics. 2019. https://www.emaeuropaeu/en/documents/product-information/rinvoq-epar-product-information_enpdf. Accessed 1 Dec 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>EMA. Jyseleca (filgotinib): Summary of product characteristics 2020. https://www.ema.europa.eu/en/documents/product-information/jyseleca-epar-product-information_en.pdf. Accessed 1 Dec 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Gilead. Gilead receives complete response letter for filgotinib for the treatment of moderately to severely active rheumatoid arthritis 2020. https://www.gilead.com/news-and-press/press-room/press-releases/2020/8/gilead-receives-complete-response-letter-for-filgotinib-for-the-treatment-of-moderately-to-severely-active-rheumatoid-arthritis. Accessed 1 Dec 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Burmester GR, Pope JE. Novel treatment strategies in rheumatoid arthritis. Lancet. 2017;389:2338–2348.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28612748</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fleischmann R, Mysler E, Hall S, et al.  Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. Lancet. 2017;390:457–468.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28629665</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taylor PC, Keystone EC, van der Heijde D, et al.  Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2017;376:652–662.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28199814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>A study in moderate to severe rheumatoid arthritis (RA-BEAM). https://clinicaltrials.gov/ct2/show/results/NCT01710358?view=results. Accessed 1 Dec 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Fleischmann R, Pangan AL, Song IH, et al.  Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial. Arthritis Rheumatol. 2019;71:1788–1800.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31287230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Combe B, Kivitz A, Tanaka Y, et al.  LB0001 Efficacy and safety of filgotinib for patients with rheumatoid arthritis with inadequate response to methotrexate: FINCH1 primary outcome results. Ann Rheum Dis. 2019;78(S2):77–78.</Citation>
        </Reference>
        <Reference>
          <Citation>Lee EB, Fleischmann R, Hall S, et al.  Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014;370:2377–2386.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24941177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fleischmann R, Schiff M, van der Heijde D, et al.  Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheumatol. 2017;69:506–517.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5347954</ArticleId>
            <ArticleId IdType="pubmed">27723271</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Vollenhoven R, Takeuchi T, Pangan A, et al.  Efficacy and safety of upadacitinib monotherapy in methotrexate-naïve patients with moderately to severely active rheumatoid arthritis (SELECT-EARLY): a randomized, double-blind, active-comparator, multi-center, multi-country trial. Arthritis Rheumatol. 2020;72:1607–1620.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7589375</ArticleId>
            <ArticleId IdType="pubmed">32638504</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Westhovens R, Rigby W, van der Heijde D, et al.  LB0003 EFficacy and safety of filgotinib for patients with rheumatoid arthritis naïve to methotrexate therapy: FINCH3 primary outcome results. Ann Rheum Dis. 2019;78(S2):259–261.</Citation>
        </Reference>
        <Reference>
          <Citation>Genovese MC, Kalunian K, Gottenberg JE, et al.  Effect of filgotinib vs. placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: The FINCH 2 randomized clinical trial. JAMA. 2019;322:315–325.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6652745</ArticleId>
            <ArticleId IdType="pubmed">31334793</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol. 2017;13:234.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28250461</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>EMA. EMA confirms Xeljanz to be used with caution in patients at high risk of blood clots 2019. https://www.ema.europa.eu/en/medicines/human/referrals/xeljanz. Accessed 1 Dec 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Taylor PC, Weinblatt ME, Burmester GR, et al.  Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis. Arthritis Rheumatol. 2019;71:1042–1055.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6618316</ArticleId>
            <ArticleId IdType="pubmed">30663869</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parmentier JM, Voss J, Graff C, et al.  In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494) BMC Rheumatol. 2018;2:23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6390583</ArticleId>
            <ArticleId IdType="pubmed">30886973</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanaka Y. A review of upadacitinib in rheumatoid arthritis. Mod Rheumatol. 2020;30:1–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32530345</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>FDA. RINVOQ (upadacitinib) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211675s000lbl.pdf2019. Accessed 1 Dec 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Rubbert-Roth A, Enejosa J, Pangan A, et al.  Efficacy and safety of upadacitinib versus abatacept in patients with active rheumatoid arthritis and prior inadequate response or intolerance to biologic disease-modifying anti-rheumatic drugs (SELECT-CHOICE): a double-blind, rnadomized controlled Phase 3 trial [Abstract] Ann Rheum Dis. 2020;79:1011.</Citation>
        </Reference>
        <Reference>
          <Citation>Kameda H, Takeuchi T, Yamaoka K, et al.  Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study. Rheumatology (Oxford) 2020;59:3303–3313.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7590414</ArticleId>
            <ArticleId IdType="pubmed">32277824</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fries JF, Spitz P, Kraines G, et al.  Measurement of patient outcome in arthritis. Arthritis Rheum. 1980;23:137–145.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7362664</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Orbai AM, Bingham CO., 3rd Patient reported outcomes in rheumatoid arthritis clinical trials. Curr Rheumatol Rep. 2015;17:28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4404708</ArticleId>
            <ArticleId IdType="pubmed">25854489</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol. 2000;27:261–263.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10648051</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cohen SB, van Vollenhoven R, Winthrop KL, et al.  Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Ann Rheum Dis. 2020 doi: 10.1136/annrheumdis-2020-218510.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2020-218510</ArticleId>
            <ArticleId IdType="pmc">PMC7892382</ArticleId>
            <ArticleId IdType="pubmed">33115760</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cohen SB, van Vollenhoven R, Curtis JR, et al.  Safety profile of upadacitinib up to 3 years of exposure in patients with rheumatoid arthritis [THU0197] Ann Rheum Dis. 2020;79:315.</Citation>
        </Reference>
        <Reference>
          <Citation>Winthrop K, Nash P, Yamaoka K, et al.  Incidence and risk factors for herpes zoster in rheumatoid arthritis patients receiving upadacitinib [THU0218] Ann Rheum Dis. 2020;79:331.</Citation>
        </Reference>
        <Reference>
          <Citation>Winthrop K, Calabrese LH, Van den Bosch F, et al.  Characterization of serious infections with upadacitinib in patients with rheumatoid arthritis [FRI0141] Ann Rheum Dis. 2020;79:650.</Citation>
        </Reference>
        <Reference>
          <Citation>Choy E, McInnes I, Cush J, et al.  Incidence and risk of venous thromboembolic events among patients with rheumatoid arthritis enrolled in the upadacitinib SELECT clinical trial program [THU0195] Ann Rheum Dis. 2020;79:313.</Citation>
        </Reference>
        <Reference>
          <Citation>Burmester GR, Kremer JM, Van den Bosch F, et al.  Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391:2503–2512.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29908669</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Genovese MC, Fleischmann R, Combe B, et al.  Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet. 2018;391:2513–2524.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29908670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burmester G, van den Bosch F, Bassette L, et al.  Long-term safety and efficacy of upadacitinib in patients with rheumatoid arthritis and an inadequate response to csDMARDs: results at 60 weeks from the SELECT-NEXT study. Ann Rheum Dis. 2019;78:735–736.</Citation>
        </Reference>
        <Reference>
          <Citation>Genovese MC, Combe B, Hall S, et al.  Upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological DMARDs: results at 60 weeks from the SELECT-BEYOND study. Ann Rheum Dis. 2019;78:360–361.</Citation>
        </Reference>
        <Reference>
          <Citation>Fleischmann RM, Genovese MC, Enejosa JV, et al.  Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response. Ann Rheum Dis. 2019;78:1454–1462.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6837258</ArticleId>
            <ArticleId IdType="pubmed">31362993</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smolen JS, Pangan AL, Emery P, et al.  Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet. 2019;393:2303–2311.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31130260</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smolen J, Emery P, Rigby W, et al. Upadacitinib as monotherapy in patients with rheumatoid arthritis: results at 48 weeks [abstract]. Arthritis Rheumatol. 2019;71(suppl 10).</Citation>
        </Reference>
        <Reference>
          <Citation>van Vollenhoven R, Takeuchi T, Pangan A, et al.  Monotherapy with upadacitinib in MTX-naive patients with rheumatod arthritis: results at 48 weeks from the SELECT-EARLY study. Ann Rheum Dis. 2019;78:376–377.</Citation>
        </Reference>
        <Reference>
          <Citation>FDA. Tofacitinib Medical Review. Application Number 203214Orig1s000 2012. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203214Orig1s000MedR.pdf. Accessed 1 Dec 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>FDA. Tocilizumab Medical Review. Application Number 125276. 2009. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/125276s000MedR.pdf. Accessed 1 Dec 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>FDA. Sarilumab Medical Review. Application Number 761037Orig1s000 2017. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761037Orig1s000MedR.pdf. Accessed 1 Dec 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Tanaka Y, Ishii T, Cai Z, et al.  Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis: a 52-week, randomized, single-blind, extension study. Mod Rheumatol. 2018;28:20–29.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28440680</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Winthrop KL, Yamanaka H, Valdez H, et al.  Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014;66:2675–2684.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4285807</ArticleId>
            <ArticleId IdType="pubmed">24943354</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harigai M, Imafuku S, Sasaki N, et al. Incidence and risk factors for herpes zoster (HZ) in Japanese and global rheumatoid arthritis (RA) populations receiving upadacitinib (UPA). In: The 64th Annual Meeting of the Japanese Society of Rheumatology, 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Yamaoka K, Tanaka Y, Kameda H, et al. Safety profile of upadacitinib (UPA) in Japanese patients (pts) with rheumatoid arthritis (RA). In: The 64th Annual Meeting of the Japanese Society of Rheumatology, 2020;20(Suppl).</Citation>
        </Reference>
        <Reference>
          <Citation>FDA. Baricitinib, a JAK inhibitor for RA. Briefing Information for the April 23, 2018 Meeting of the Arthritis Advisory Committee (AAC). https://www.fda.gov/media/112372/download. Accessed 1 Dec 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Simon TA, Thompson A, Gandhi KK, et al.  Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. Arthritis Res Ther. 2015;17:212.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4536786</ArticleId>
            <ArticleId IdType="pubmed">26271620</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roubille C, Richer V, Starnino T, et al.  The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74:480–489.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4345910</ArticleId>
            <ArticleId IdType="pubmed">25561362</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choy E, McInnes I, Cush J, et al. MACE and VTE across multiple upadacitinib studies in rheumatoid arthritis: integrated analysis from the SELECT phase 3 clinical program [abstract]. Arthritis Rheumatol. 2019;71(suppl 10).</Citation>
        </Reference>
        <Reference>
          <Citation>Kim SC, Schneeweiss S, Liu J, et al.  Risk of venous thromboembolism in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2013;65:1600–1607.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4090802</ArticleId>
            <ArticleId IdType="pubmed">23666917</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kroegel C, Reissig A. Principle mechanisms underlying venous thromboembolism: epidemiology, risk factors, pathophysiology and pathogenesis. Respiration. 2003;70:7–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12584387</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Queeney K, Housley W, Sokolov J, et al.  FRI0131 Elucidating the mechanism underlying creatine phosphokinase upregulation with upadacitinib. Ann Reum Dis. 2019;78(S2):734–735.</Citation>
        </Reference>
        <Reference>
          <Citation>Nash P, Kerschbaumer A, Dörner T, et al.  Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Ann Rheum Dis. 2020;80:71–87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7788060</ArticleId>
            <ArticleId IdType="pubmed">33158881</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mohamed MF, Klünder B, Othman AA. Clinical pharmacokinetics of upadacitinib: review of data relevant to the rheumatoid arthritis indication. Clin Pharmacokinet. 2020;59:531–544.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7217812</ArticleId>
            <ArticleId IdType="pubmed">31867699</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klünder B, Mittapalli RK, Mohamed MF, et al.  Population pharmacokinetics of upadacitinib using the immediate-release and extended-release formulations in healthy subjects and subjects with rheumatoid arthritis: analyses of phase I-III cinical trials. Clin Pharmacokinet. 2019;58:1045–1058.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6614152</ArticleId>
            <ArticleId IdType="pubmed">30945116</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pavelka K, Szekanecz Z, Damjanov N, et al.  Upadacitinib versus placebo or adalimumab with background methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate: a subgroup analysis of a phase III randomized controlled trial in Central and Eastern European patients. Drugs Context. 2020;9:2020-7-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7574850</ArticleId>
            <ArticleId IdType="pubmed">33123205</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takeuchi T, Rischmueller M, Blanco R, et al. Upadacitinib monotherapy versus methotrexate monotherapy in methotrexate-naïve Japanese patients with rheumatoid arthritis: a sub-analysis of the Phase 3 SELECT-EARLY study. Mod Rheumatol. 2020:1–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33164611</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zeng X, Zhao D, Radominski S, et al.  SAT0160 Efficacy and safety of upadacitinib in patients from China, Brazil, and South Korea with rheumatoid arthritis who have had inadequate response to conventional synthetic disease-modifying antirheumatic drugs. Ann Rheum Dis. 2020;79(S1):1020–1021.</Citation>
        </Reference>
        <Reference>
          <Citation>A study to compare upadacitinib (ABT-494) monotherapy to methotrexate (MTX) monotherapy in adults with rheumatoid arthritis (RA) who have not previously taken methotrexate (SELECT-EARLY) https://clinicaltrials.gov/ct2/show/NCT02706873. Accessed 1 Dec 2020.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
